Furosemide Stress Test as a Marker of Postoperative Kidney Allograft Function

What this Trial Is About

This research aims to evaluate the response to a standardized dose of furosemide in patients who have undergone kidney transplantation. The study focuses on measuring urine output after administering furosemide as a way to predict early kidney graft function in the perioperative period. This approach addresses a gap, as no previous study has directly assessed urine response to a standardized furosemide dose post-transplant. Participants receive a single intravenous dose of furosemide at 1.5 mg/kg three hours after the kidney allograft is reperfused. Urine output is then recorded hourly for six hours following the dose. This intervention is assessed as an experimental approach to understand its role as a biomarker for kidney function after transplantation. Throughout the study, urine output is closely monitored for six hours after furosemide administration, and additional outcomes such as delayed graft function over seven days and creatinine reduction ratio on postoperative days 0, 7, and 14 are evaluated. The study involves follow-up assessments to track kidney function and graft performance, providing important data on early postoperative kidney health. Participants remain under observation to measure these outcomes until the study concludes.

Furosemide Stress Test Predicting Early Graft Function in Kidney Transplantation